Device Week Podcast – Episode 23
This article was originally published in The Gray Sheet
On this week's podcast, "Gray Sheet" reporters discuss FDA postapproval studies, more on the hospital ICD settlement, unexpected provisions in a Medicare coverage proposal for Boston Scientific's Watchman device, the launch of the US high-intensity focused ultrasound market for prostate cancer, and mobile health and cybersecurity issues raised at this year's mHealth Summit.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.